Cytokinetics (CYTK) / Amgen (AMGN) Omecamtiv Data In-line With Expectations - Leerink Swann
Tweet Send to a Friend
Leerink Swann maintained an Outperform rating on Cytokinetics (NASDAQ: CYTK) with a price target of $20.00. Comments follow news from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
